5 completed, 1 terminated, 1 unknown. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Community-acquired Bacterial Pneumonia: new trials by email Literature Review of Community-acquired Bacterial Pneumonia trials Research Report on Community-acquired Bacterial Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP Omadacycline, Moxifloxacin - Community-acquired Bacterial Pneumonia | Phase 3 | Unknown | Zai Lab (Hong Kong), Ltd. | 100 | 2023-11-17 | 2024-06-14 |
| Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia Solithromycin, Standard of Care - Community-acquired Bacterial Pneumonia | Phase 2 / Phase 3 | Terminated | Melinta Therapeutics, Inc. | 97 | 2016-04-01 | 2019-01-03 |
| Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia Solithromycin, Moxifloxacin - Community-acquired Bacterial Pneumonia | Phase 3 | Completed | Melinta Therapeutics, Inc. | 863 | 2013-11-01 | 2017-03-03 |
| Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia Solithromycin, Moxifloxacin, Placebo to match solithromycin - Community-acquired Bacterial Pneumonia | Phase 3 | Completed | Melinta Therapeutics, Inc. | 860 | 2012-12-01 | 2017-03-03 |
| A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia Ceftaroline, Ceftriaxone - Community-Acquired Bacterial Pneumonia, Lung Infection of Individual Not Recently Hospitalized | Phase 3 | Completed | Pfizer | 848 | 2011-12-01 | 2017-09-06 |
| Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia Levofloxacin, CEM-101 - Community-Acquired Bacterial Pneumonia | Phase 2 | Completed | Melinta Therapeutics, Inc. | 132 | 2010-08-01 | 2017-03-03 |
| Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment tigecycline - Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections | Completed | Pfizer | 3172 | 2010-05-01 | 2023-12-29 |
Pneumonia (3) · Infections (1)
Infections (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3)
solithromycin (4) · Moxifloxacin (3) · Ceftriaxone (2) · Amoxicillin (1) · Amoxicillin-Potassium Clavulanate Combination (1) · Ampicillin (1) · Azithromycin (1) · Ceftaroline (1) · Erythromycin (1) · Levofloxacin (1) · Standard of Care (1) · Tigecycline (1) · erythromycin lactobionate (1) · omadacycline (1)
Melinta Therapeutics, Inc. (4) · Pfizer (2) · Zai Lab (Hong Kong), Ltd. (1)
United States (4) · Bulgaria (3) · Canada (3) · Hungary (3) · South Korea (3) · Spain (3) · Argentina (2) · China (2) · Germany (2) · Latvia (2) · Philippines (2) · Poland (2) · Romania (2) · Russia (2) · South Africa (2)
Brian D Jamieson, MD (1) · David Melnick (1) · David Oldach, MD (1) · Haihui Huang, PhD (1) · Michael Cohen-Wolkowiez, MD, PhD (1)
PMID 23507282, PMID 25539586, PMID 26702925, PMID 26852726, PMID 27448679, PMID 30380060, PMID 30597021, PMID 31044546, PMID 34922058, PMID 35237053